Skip to main content

Table 2 Discriminating features from orthogonal projections to latent structures discriminant analysis with identification of lipid structure

From: Metabolic status of CSF distinguishes rats with tauopathy from controls

Name p1 pcorr1 Fold change p Value (α = 1.28E-04)a Ion m/z Error ppm Formula MSI level
Cerebrospinal fluid
 PC(P-36:3)/PC(O-36:4) −4.44 −0.98 0.22 1.96E-10 [M + H]+ 768.5901 −0.13 C44H83NO7P 3
 PC −3.54 −0.98 0.36 8.43E-10 [M + H]+ 703.5747 3
 PC(17:0/18:1)/PC(35:1) −3.96 −0.98 0.28 1.66E-09 [M + H]+ 774.6004 −0.43 C43H85O8NP 2
 PC(P-36:4)/PC(O-36:5) −3.65 −0.97 0.29 5.08E-08 [M + H]+ 766.574 −0.65 C44H81NO7P 3
 PC(16:0/18:2)/PC(34:2) −3.41 −0.97 0.39 6.21E-08 [M + H]+ 758.5691 −0.4 C42H81O8NP 2
 LysoPC(18:1) −3.42 −0.96 0.39 1.13E-07 [M + H]+ 522.3553 −0.19 C26H53O7NP 2
 PC(18:0/18:1)/PC(36:1) −2.98 −0.96 0.51 1.04E-06 [M + H]+ 788.6161 −0.36 C44H87O8NP 2
 PC(16:0/18:1)/PC(34:1) −2.86 −0.96 0.53 1.31E-06 [M + H]+ 760.5847 −0.5 C42H83O8NP 2
 PC(P-36:2)/PC(O-36:3) −4.35 −0.95 0.19 4.26E-07 [M + H]+ 770.6056 −0.25 C44H85NO7P 3
 PC(16:0/20:4)/PC(36:4) −3.03 −0.95 0.46 9.59E-07 [M + H]+ 782.567 −3.07 C44H81O8NP 2
 Unknown compound −2.78 −0.95 0.57 1.42E-05 [M + H]+ 850.5542 4
 PC(C18:0/20:4)/PC(38:4) −2.54 −0.95 0.57 1.44E-05 [M + H]+ 811.6043 –5.25 C46H86O8NP 2
 PC −3.9 −0.94 0.31 2.95E-08 [M + H]+ 813.6836 3
 PC(16:0/16:1)/PC(32:1) −2.7 −0.93 0.39 1.67E-07 [M + H]+ 732.5537 −0.11 C40H79O8NP 2
 PC(16:0/16:0)/PC(32:0) −2.7 −0.93 0.51 1.89E-05 [M + H]+ 734.5692 −0.32 C40H81O8NP 2
 PC(16:0/18:3)/PC(16:1/18:2)/PC(34:3) −2.78 −0.92 0.5 2.88E-05 [M + H]+ 756.5513 −3.28 C42H79O8NP 2
 PC −2.2 −0.91 0.66 9.11E-05 [M + H]+ 731.6058 3
 LysoPC(16:0) −3.01 −0.89 0.44 9.53E-05 [M + H]+ 496.3397 −0.2 C24H51O7NP 2
Name p1 pcorr1 fold change p Value (α =6.56E-05)a ion m/z error ppm formula MSI level
Plasma
 PC(42:9) −3.51 −0.93 0.63 2.21E-04 [M + H]+ 856.5815 −4.2 C50H83NO8P 3
 PC(18:0/22:6)/PC(18:1/22:5)/PC(40:6) −3.37 −0.93 0.66 1.35E-04 [M + H]+ 834.5997 −1.19 C48H85NO8P 2
 PC −3.01 −0.92 0.68 1.16E-04 [M + H]+ 807.571 3
 PC −4.1 −0.92 0.54 1.08E-04 [M + H]+ 829.0515 3
 PC(20:2/0:0) 4.01 0.9 1.63 4.33E-03 [M + H]+ 548.3705 −1.09 C28H55O7NP 2
 PC −3.08 −0.9 0.79 8.78E-03 [M + H]+ 792.6278 3
 PC(18:0/18:1)/PC(36:1) −2.6 −0.88 0.82 1.14E-02 [M + H]+ 788.6164 −0.03 C44H87NO8P 2
 PC −2.91 −0.87 0.74 1.56E-03 [M + H]+ 892.6534   3
 PC −3.53 −0.86 0.64 6.31E-04 [M + H]+ 859.59 3
 PC −3.34 −0.83 0.7 1.30E-03 [M + H]+ 992.5569 3
 PC(P-40:3)/PC(O-40:4) −2.61 −0.82 0.73 5.59E-03 [M + H]+ 824.6524 −0.48 C48H91NO7P 3
 PC −2.68 −0.81 0.87 5.91E-02 [M + H]+ 764.5976 9.88 C41H83O9NP 3
 PC(16:0/16:0)/PC(32:0) −2.12 −0.79 0.9 5.38E-02 [M + H]+ 734.5702 1.09 C40H81O8NP 2
 LysoPC(20:3) 2.61 0.77 1.2 1.20E-01 [M + H]+ 546.3546 −1.46 C28H53O7NP 2
 PC(20:0/0:0) 2.75 0.77 1.3 6.72E-03 [M + H]+ 552.402 −0.72 C28H59O7NP 2
 LysoPC(22:5) 3.15 0.76 1.39 7.30E-02 [M + H]+ 570.3545 −1.58 C30H53NO7P 2
  1. Abbreviations: MSI Metabolomics Standards Initiative, m/z Mass-to-charge ratio, PC Phosphatidylcholine
  2. p Values and fold change for these features are depicted
  3. a Corrected α value (after Bonferroni correction)